CD64 binding potential does not translate into enhanced therapeutic efficacy for anti-IL-23 antibodies under physiologically relevant conditions - PubMed
3 hours ago
- #Therapeutic efficacy
- #Anti-IL-23 antibodies
- #CD64 binding
- Anti-IL-23 antibodies with CD64 binding potential did not show enhanced therapeutic efficacy under physiologically relevant conditions.
- The research involved in vitro experiments with human PBMCs and animal models, with ethical approvals and informed consent obtained.
- AbbVie funded the study, and many authors are AbbVie employees or have financial ties, including stock ownership and consulting roles.
- Conflicts of interest include various authors receiving funding from multiple pharmaceutical companies for consulting, advisory, or speaker roles.
- The study references guidelines for laboratory animal care and prescribing information for related drugs like risankizumab.